Roivant Sciences targets brepocitinib expansion with new cutaneous sarcoidosis trial amid $5.2B cash position Roivant Sciences targets brepocitinib expansion with new cutaneous sarcoidosis trial amid $5.2B cash position Post ContentroivRead More You might also be interested in reading Europe Prefers SHIB Over DOGE. February 10, 2025 In Mainstream ← Previous post Next post →